嚎托澳彼治疗慢性阻塞性肺疾病疗效观察［摘要］目的：评价嚓托溟銭治疗慢性阻塞性肺疾病的疗效。方法：86例稳定期COPD患者随机平均分为嚓托漠銭纟fl和对照纟fl。对照纟fl给予常规治疗，嚓托溟馈组在对照组治疗的基础上给予每口1次18Ug®托澳馁经干粉髀吸入，两组均治疗12周，观察两组治疗前后肺功能改变情况［一秒钟用力呼气量(FEV1)和FEV1/用力肺活量(FVC)］、运动耐力改变(6min步行距离)和生活质最评分变化，并评价不良反应发生情况。结果：两组治疗前FEV1、FEV1/FVC、6min步行距离、生活质量评分比较，差异无统计学意义(P>0.05)。嚓托漠馁组治疗后FEVkFEVl/FVC均较治疗前提高［(46.23土11.02)%vs(39.19±7,47)%,t=3.237,1X0.05；(59.70±9・42)%vs(55.46土8.25)%,t二2.974,P<0・05］。治疗后曝托漠钱组FEVKFEV1/FVC均较对照组改善明显［对照组FEV1(43.11±8.93)%,1=2.630,P<0.05；FEV1/FVC(55・73±9.91)%,t二2.857,PC0.05］。唾托澳镀组治疗前后FEV1改善率平均为(17.92±5.43)%,对照组为(6.41±3.98)%,两组比较，差异有统计学意义(t=2・73,P<0.05)o唾托漠钱组治疗后6min步行距离较治疗前提高［(351.2±43.7)mvs(271.3±39.0)m,t=3.090,P<0.05］,较对照组改善明显［对照组(299.5±56.4)m,t=3.012,P<0.05］0®托漠钱组治疗后生活质量评分较治疗前提高［(57.4±6.1)分vs(39.7土5.9)分，t=2.538,P<0.05］o治疗后唾托澳钱组生活质量评分较对照组高［(42.1+6.0)分，t二3.204,P〈0.05］。两组均未发生严重不良反应。结论：嚓托漠僅治疗稳定期C0PD患者用药安全有效，可在临床上推广使用。［关键词］慢性阻塞性肺疾病；唾托漠镀；疗效［中图分类号］R563；R974［文献标识码］A［文章编号11673-7210(2011)07(c)-067-03TheefficacyobservationofTiotropiumBromideinthetreatmentofstablechronicobstructivepulmonarydiseaseLIANGXianmeiDepartmentofRespiratoryMedicine,theSecondPeople'sHospitalofGuilinCity,theGuangxiZhuangAutonomousRegion,Guilin541001,China［Abstract］Objective:ToevaluatetheefficacyofTiotropiumBromideinthetreatmcntofstablechronicobstructivepulmonarydisease(COPD).Methods:Atotalof86patientswithstableCOPDwererandomlydividedintoTiotropiumBromidegroup(43cases)andcontrolgroup(43cases)・Controlgroupwasgivenroutinetreatmentandbesidesthat,TiotropiumBromidegroupwasgiveninhaled18ugTiotropiumBromideonceaday,thetwogroupsweretreatedfor12weeks,thenpulinonaryfunctionchange(FEV1andEEVI/FVC),exercisetoleraneechange(6minwalkdistance)andqualityoflifescorechangebeforeandaftertreatmentinthetwogroupswereobserved,andtheadverseeffectswerealsoevaluated.ResuIts:FEV1,FEV1/FVC,6minwalkdistanceandqualityoflifescorebeforetreatrnentinthetwogroupsshowednostatisticaldifference(P>0.05).FEV1andFEV1/FVCaftertreatmentinTiotropiumBromidegroupwereimprovedthanthosebeforetreatment［(46.23±11.02)%vs(39.19±7.47)%,t=3.237,P<0.05;(59.70±9.42)%vs(55.46土&25)%,t=2.974,P<0.05］.Aftertreatment,FEV1andFEV1/FVCinTiotropiumBromidegroupwashigherthanthoseincontrolgroup［controlgroup:FEV1(43.11±8.93)%,t=2.630,P<0.05;FEV1/FVC(55.73±9.91)%,t=2.857,P<0.05].FEV1improvement,ratebeforeandaftertreatmentinTiotropiumBromidegroupandcontrolgroupwere(17.92±5.43)%and(6.41±3.98)%respectively,thereweresignificantdifference(t=2.73,P<0.05)・6minwalkdistanceaftertreatmentinTiotropiumBromidegroupwasimprovedthanthatbeforetreatment[(351.2±43.7)mvs(271.3±39.0)m,t=3.090,P<0.05],anditwashigherthancontrolgroup[(299.5±56.4)m,t=3.012,P<0.05].QualityoflifeaftertreatmentofTiotropiumBromidegroupwashigherthanthatbeforetreatment[(57.4±6.1)scorevs(39.7±5.9)score,t二2.538,P<0.05],anclitwasalsohigherthanthatofcontrolgroup[(42.1±6.0)score,t=3.204,P<0.05].Nosevereadverseeffectwaso...